CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
TRC105 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01326481
NCT01326481Phase 2Completed
CompareCT.gov

An Open Label Phase 1B Dose-Finding Study of TRC105 in Combination With Capecitabine for Progressive or Recurrent Metastatic Breast Cancer

Tracon Pharmaceuticals Inc.·interventional·Posted Mar 31, 2011·Updated Mar 18, 2019

In Brief

A Phase 2 clinical trial evaluating TRC105 and Capecitabine for Metastatic Breast Cancer. Completed, enrolled 19 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine the recommended phase 2 dose and overall safety and tolerability of TRC105 when given in combination with capecitabine for the treatment of patients with progressive or recurrent metastatic breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesUnited States
CollaboratorsRoswell Park Cancer Institute, United States Department of Defense

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 31, 2011
Enrollment StartJun 1, 2011
Primary CompletionSep 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.3 years ago

Interventions

TRC105drug

IV

Capecitabinedrug

oral